MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications

Key findings that underscore the power of MolecuLight imaging: Key findings that underscore the power of MolecuLight imaging: "This study demonstrates that MolecuLight delivers tangible benefits in clinical wound management and also serves as a valuable teaching tool in our daily practice. The ability to visualize bacterial presence in real time allows us to more effectively guide younger physicians in understanding critical principles of infection control and intraoperative wound assessment...

Key findings that underscore the power of MolecuLight imaging:

"This study demonstrates that MolecuLight delivers tangible benefits in clinical wound management and also serves as a valuable teaching tool in our daily practice. The ability to visualize bacterial presence in real time allows us to more effectively guide younger physicians in understanding critical principles of infection control and intraoperative wound assessment. Moving forward, we intend to continue using this technology to enhance clinical decision-making and overall patient care," said study author Dr. Shun-Cheng Chang, from Shuang-Ho Hospital.

"We are honored to introduce MolecuLight's advanced real-time fluorescence imaging technology to Taiwan," remarked Wei-Pin Hsieh, CEO of Healtdeva Company Ltd. "This innovation provides clinicians with a more efficient and accurate tool for assessing infections, opening new diagnostic perspectives in the management of complex wounds and post-operative care. We firmly believe that this technology will have a profound impact on improving patient outcomes and reducing overall healthcare costs."

This study underscores the growing recognition of MolecuLight's significant utility beyond chronic wound care and its increasing adoption in critical surgical applications. The company's advanced imaging system, with its unique ability to visualize bacterial presence in real-time and guide targeted interventions, is gaining traction among surgeons looking to optimize outcomes and better manage post-operative complications in various surgical procedures, including the management of deep sternal wound infections (DSWI).

"We wish to commend the researchers for their excellent work on this study," said Anil Amlani, CEO of MolecuLight. "These compelling results further validate the significant clinical and economic value of MolecuLight's technology, not only in chronic wound care but also in critical surgical applications. This study, along with our growing adoption in surgical settings, reflects the increasing recognition of our ability to provide critical, real-time information that empowers clinicians to make better decisions at the point of care, ultimately improving patient outcomes and reducing the burden of post-operative complications. We are proud to partner with Healtdeva Company to bring these benefits to patients in Taiwan."

About MolecuLight Inc.
MolecuLight Inc. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X^® and DX^™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.

About Healtdeva Company Ltd.
Healtdeva Company Ltd. was established in 1992 and is based in Taipei, Taiwan. Healtdeva Company Ltd. is a trusted distributor of medical technologies and healthcare solutions, with a well-established network across hospitals, clinics, and retail pharmaceuticals, advanced wound care, infection control, and preventive health. Healtdeva Company partners with global innovators to bring cutting-edge medical solutions to the Taiwanese market, driving clinical adoption and commercial success through localized expertise and strategic channel integration.

Photo - https://mma.prnewswire.com/media/2708971/MolecuLight_MolecuLight_%C2%A0Imaging_Significantly_Improves_Outcomes.jpg 

Logo - https://mma.prnewswire.com/media/2708970/MolecuLight_MolecuLight_%C2%A0Imaging_Significantly_Improves_Outcomes.jpg

View original content:https://www.prnewswire.co.uk/news-releases/moleculight-imaging-significantly-improves-outcomes-and-cuts-costs-for-deep-sternal-wound-infections-in-taiwan-study-signals-expansion-into-surgical-applications-302479677.html